NO942641L - Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav - Google Patents

Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Info

Publication number
NO942641L
NO942641L NO942641A NO942641A NO942641L NO 942641 L NO942641 L NO 942641L NO 942641 A NO942641 A NO 942641A NO 942641 A NO942641 A NO 942641A NO 942641 L NO942641 L NO 942641L
Authority
NO
Norway
Prior art keywords
phosphatidylinositol
kinase
wortmannin
inhibition
analogs
Prior art date
Application number
NO942641A
Other languages
English (en)
Norwegian (no)
Other versions
NO942641D0 (no
Inventor
Rosanne Bonjouklian
Garth Powis
Chris John Vlahos
Original Assignee
Lilly Co Eli
Arizona Board Of Regents The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Arizona Board Of Regents The filed Critical Lilly Co Eli
Publication of NO942641D0 publication Critical patent/NO942641D0/no
Publication of NO942641L publication Critical patent/NO942641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO942641A 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav NO942641L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (2)

Publication Number Publication Date
NO942641D0 NO942641D0 (no) 1994-07-14
NO942641L true NO942641L (no) 1995-01-20

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942641A NO942641L (no) 1993-07-19 1994-07-14 Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav

Country Status (16)

Country Link
US (1) US5378725A (enExample)
EP (1) EP0635268A1 (enExample)
JP (1) JPH0753370A (enExample)
KR (1) KR950002755A (enExample)
CN (1) CN1111127A (enExample)
AU (1) AU678831B2 (enExample)
CA (1) CA2128046A1 (enExample)
CZ (1) CZ283806B6 (enExample)
HU (1) HUT67667A (enExample)
IL (1) IL110325A0 (enExample)
NO (1) NO942641L (enExample)
PH (1) PH30794A (enExample)
PL (1) PL304317A1 (enExample)
RU (1) RU94026082A (enExample)
TW (1) TW287102B (enExample)
ZA (1) ZA945103B (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
AU770896C (en) * 1998-09-29 2006-09-07 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
EP2108377A1 (en) * 1998-03-24 2009-10-14 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
ES2384160T3 (es) * 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6566081B1 (en) 1999-10-06 2003-05-20 The Brigham And Women's Hospital, Inc. Methods of identifying a compound which modulates the non-transcriptional non-map-kinase induced effects of steroid hormones
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU6513701A (en) * 2000-05-30 2001-12-11 Advanced Res & Tech Inst Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
EP1542703A4 (en) * 2002-07-10 2007-11-07 Massachusetts Inst Technology SOLID PHASE AND SOLUTION PHASE SYNTHESIS OF GLYCOSYL PHOSPHATIDYLINOSITOL GLYCANES
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
AU2004217699B2 (en) * 2003-03-07 2008-07-03 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of PI 3-kinase
CA2522980A1 (en) * 2003-04-23 2004-11-04 Wyeth Holdings Corporation Water soluble wortmannin derivatives
DK1626714T3 (da) * 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
MXPA06001599A (es) 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
ES2607804T3 (es) 2004-05-13 2017-04-04 Icos Corporation Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
RU2408596C2 (ru) 2004-09-20 2011-01-10 Кудос Фармасьютикалс Лимитед Ингибиторы днк-пк
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
JP2008529995A (ja) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド Ａｔｍ阻害剤
EP1885356A2 (en) * 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
JP2008543277A (ja) * 2005-05-11 2008-12-04 ジェネティック テクノロジーズ リミテッド 胎児細胞を富化する方法
AU2006251428A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20080199441A1 (en) * 2006-11-09 2008-08-21 Tony Peled Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CN104204192A (zh) 2012-02-13 2014-12-10 加米达细胞有限公司 间充质干细胞调理的基质及其产生和使用方法
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
AU6754094A (en) 1995-01-27
JPH0753370A (ja) 1995-02-28
US5378725A (en) 1995-01-03
NO942641D0 (no) 1994-07-14
CZ169294A3 (en) 1995-02-15
PL304317A1 (en) 1995-01-23
IL110325A0 (en) 1994-10-21
RU94026082A (ru) 1996-05-20
ZA945103B (en) 1996-03-27
HUT67667A (en) 1995-04-28
EP0635268A1 (en) 1995-01-25
PH30794A (en) 1997-10-17
AU678831B2 (en) 1997-06-12
CA2128046A1 (en) 1995-01-20
TW287102B (enExample) 1996-10-01
CZ283806B6 (cs) 1998-06-17
CN1111127A (zh) 1995-11-08
KR950002755A (ko) 1995-02-16
HU9402128D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
NO942641L (no) Inhibisjon av fosfatidylinositol 3-kinase med wortmannin og analoger derav
SE8503680D0 (sv) Indolderivat
EP0534363A3 (en) Novel 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
GR3021420T3 (en) 2-Substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
DE69516866D1 (de) Stereochemische wortmanninderivate
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
NO996578L (no) Urokinase-inhibitorer
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
ATE164593T1 (de) Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK599789D0 (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
MX9303145A (es) 7-(2-aminoetil)benzotiazolonas.
DE69102936D1 (de) Bis(alkyl-substituierte-4-hydroxyphenylthio)alkan-Analoga als Inhibitoren der Kataraktentstehung.
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
NO891703L (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
ES2171553T3 (es) Derivados de quinoxalina utiles en terapia.
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DK318589A (da) 19-substituerede progesteron-derivater, anvendelige som 19-hydroxylase-inhibitorer
ES8707495A1 (es) Un procedimiento para preparar derivados de azetidinona
AU2291483A (en) Carbamyloxybenzhyrol derivatives
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
EP0521080A4 (en) Synergistic compositions
IL89901A (en) Strobilurine derivative
AR005866A1 (es) Composicion farmaceutica antioxidante